These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2866787)

  • 1. Chloroquine decreases oral-caecal transit time.
    Adjepon-Yamoah KK; Woolhouse NM; Ofori-Adjei D; Nortey LN
    Br J Clin Pharmacol; 1985 Oct; 20(4):425-6. PubMed ID: 2866787
    [No Abstract]   [Full Text] [Related]  

  • 2. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
    Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
    Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
    [No Abstract]   [Full Text] [Related]  

  • 3. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
    Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
    Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.
    Fischer C; Klotz U
    J Chromatogr; 1979 Feb; 162(2):237-43. PubMed ID: 33196
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys.
    Kondo H; Watanabe T; Yokohama S; Watanabe J
    Biopharm Drug Dispos; 2003 May; 24(4):141-51. PubMed ID: 12698497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The variability of orocecal transit time evaluated by the salicylazosulphapyridine/sulphapyridine method.
    Gramatté T; Terhaag B
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):147-50. PubMed ID: 1676990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study.
    Lee HJ; Waller RD; Stebbings S; Highton J; Orlovich DA; Schmierer D; Fawcett JP
    Int J Rheum Dis; 2010 Feb; 13(1):48-54. PubMed ID: 20374384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
    Pieniaszek HJ; Bates TR
    J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of sulfapyridine and its major metabolites in plasma by high pressure liquid chromatography.
    Fischer C; Klotz U
    J Chromatogr; 1978 Jul; 146(1):157-62. PubMed ID: 27529
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of human skin proteinases by chloroquine, dapsone and sulfapyridine.
    Fräki JE; Hopsu-Havu VK
    Arch Dermatol Res (1975); 1977 Jul; 259(1):113-5. PubMed ID: 900989
    [No Abstract]   [Full Text] [Related]  

  • 17. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Appearance of sulfasalazine and sulfapyridine in breast milk and in the placental barrier as well as the effect of both substances on bilirubin binding to albumin].
    Järnerot G
    Z Gastroenterol Verh; 1981 Jun; 19():27-8. PubMed ID: 6168129
    [No Abstract]   [Full Text] [Related]  

  • 19. Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.
    Rust C; Bauchmuller K; Bernt C; Vennegeerts T; Fickert P; Fuchsbichler A; Beuers U
    Gut; 2006 May; 55(5):719-27. PubMed ID: 16322111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.